Ad
related to: fda approved dose of daunorubicin
Search results
Results from the WOW.Com Content Network
Daunorubicin: Anthracycline: Cytarabine: Antimetabolite: Clinical data; Trade names ... is a fixed-dose combination medication used for the treatment of acute myeloid ...
Daunorubicin is in the anthracycline family of medication. [3] It works in part by blocking the function of topoisomerase II. [2] Daunorubicin was approved for medical use in the United States in 1979. [2] It is on the World Health Organization's List of Essential Medicines. [4] It was originally isolated from bacteria of the Streptomyces type. [5]
Anthracyclines remain some of the most widely used chemotherapeutic agents but their potential is limited by its dose-limiting toxicities. Currently, there are many studies being conducted in the search for anthracyclines with better anti-tumour efficacy or with reduced side effects using different nanotechnology-based drug delivery systems.
Liposomal daunorubicin (trade name DaunoXome) is a chemotherapy drug that is FDA approved to treat AIDS related Kaposi's sarcoma. It is also commonly used to treat specific types of leukaemia and non-Hodgkin lymphoma .
[13] [68] However, with the selective dosage, etoposide treatment is dose limiting proposing toxic effects like myelosupression (leukopenia) and primarily hematologic. [ 13 ] [ 69 ] Furthermore, around 20-30% of patients who take the recommended dosage can have hematologic symptoms such as alopecia , nausea, vomiting and stomatitis. [ 13 ]
Doxorubicin showed better activity than daunorubicin against mouse tumors, and especially solid tumors. It also showed a higher therapeutic index, yet the cardiotoxicity remained. [50] Doxorubicin and daunorubicin together can be thought of as prototype compounds for the anthracyclines. Subsequent research has led to many other anthracycline ...
Treatment of adults with locally advanced, unresectable (stage III) non- small cell lung cancer (NSCLC) whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy and whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test [2] Repotrectinib
Dexrazoxane was designated by the US FDA as an orphan drug for "prevention of cardiomyopathy for children and adults 0 through 16 years of age treated with anthracyclines". [8] This decision allows virtually all children to receive dexrazoxane starting with the first dose of anthracycline at the discretion of the treating provider.
Ad
related to: fda approved dose of daunorubicin